NO20044175L - Anvendelse av epotiloner ved behandling av hjernesykdom relatert til proliferative prosesser - Google Patents
Anvendelse av epotiloner ved behandling av hjernesykdom relatert til proliferative prosesserInfo
- Publication number
- NO20044175L NO20044175L NO20044175A NO20044175A NO20044175L NO 20044175 L NO20044175 L NO 20044175L NO 20044175 A NO20044175 A NO 20044175A NO 20044175 A NO20044175 A NO 20044175A NO 20044175 L NO20044175 L NO 20044175L
- Authority
- NO
- Norway
- Prior art keywords
- epothilones
- treatment
- disease related
- brain disease
- proliferative processes
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US36106202P | 2002-03-01 | 2002-03-01 | |
EP02004745A EP1340498A1 (en) | 2002-03-01 | 2002-03-01 | Use of epothilones in the treatment of brain diseases associated with proliferative processes |
PCT/EP2003/002085 WO2003074053A1 (en) | 2002-03-01 | 2003-02-28 | Use of epothilones in the treatment of brain diseases associated with proliferative processes |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20044175L true NO20044175L (no) | 2004-12-01 |
Family
ID=27675676
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20044175A NO20044175L (no) | 2002-03-01 | 2004-09-30 | Anvendelse av epotiloner ved behandling av hjernesykdom relatert til proliferative prosesser |
Country Status (23)
Country | Link |
---|---|
US (1) | US20040019088A1 (no) |
EP (2) | EP1340498A1 (no) |
JP (1) | JP2005525360A (no) |
KR (1) | KR20040095244A (no) |
CN (1) | CN100473381C (no) |
AR (1) | AR038712A1 (no) |
AU (1) | AU2003215618B2 (no) |
BR (1) | BR0308154A (no) |
CA (1) | CA2477403A1 (no) |
CR (1) | CR7444A (no) |
EC (1) | ECSP045340A (no) |
HK (1) | HK1079998A1 (no) |
HR (1) | HRP20040892A2 (no) |
IL (1) | IL163752A0 (no) |
MX (1) | MXPA04008450A (no) |
NO (1) | NO20044175L (no) |
NZ (1) | NZ546617A (no) |
PL (1) | PL370768A1 (no) |
RU (1) | RU2351330C2 (no) |
UA (1) | UA83798C2 (no) |
WO (1) | WO2003074053A1 (no) |
YU (1) | YU76404A (no) |
ZA (1) | ZA200407905B (no) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU756699B2 (en) | 1996-12-03 | 2003-01-23 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
AU9340998A (en) * | 1997-08-09 | 1999-03-01 | Schering Aktiengesellschaft | New epothilone derivatives, method for producing same and their pharmaceutical use |
SK11452001A3 (sk) * | 1999-02-11 | 2002-04-04 | Schering Aktiengesellschaft | Deriváty epotilónu, farmaceutický prípravok s ich obsahom a ich použitie |
AU772750C (en) * | 1999-04-30 | 2005-02-24 | Schering Aktiengesellschaft | 6-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations |
US7649006B2 (en) | 2002-08-23 | 2010-01-19 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
JP4791183B2 (ja) | 2002-08-23 | 2011-10-12 | スローン−ケッタリング インスティトュート フォア キャンサー リサーチ | エポチロン、その中間体、類似体の合成およびその使用 |
DE10331004A1 (de) * | 2003-07-03 | 2005-02-24 | Schering Ag | Verfahren für die Herstellung von C1-C15-Fragmenten von Epothilonen und deren Derivaten |
EP1559447A1 (en) * | 2004-01-30 | 2005-08-03 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Use of epothilones in the treatment of neuronal connectivity defects such as schizophrenia and autism |
US20060069136A1 (en) * | 2004-09-24 | 2006-03-30 | Ulrich Klar | Use of Epothilones in the treatment of bone metastasis |
US20060121511A1 (en) | 2004-11-30 | 2006-06-08 | Hyerim Lee | Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents |
EP1674098A1 (en) * | 2004-12-23 | 2006-06-28 | Schering Aktiengesellschaft | Stable and tolerable parental formulations of highly reactive organic drug substances with low or no solubility in water |
EP1700596A1 (en) * | 2005-03-09 | 2006-09-13 | Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E.V. | Use of microtubule stabilizing compounds for the treatment of lesions of CNS axons |
DE102007016046A1 (de) | 2007-03-30 | 2008-10-23 | Bayer Schering Pharma Aktiengesellschaft | Verfahren zur Herstellung von Epothilonderivaten durch selektive katalytische Epoxidierung |
ES2501565T3 (es) * | 2008-04-24 | 2014-10-02 | Bristol-Myers Squibb Company | Uso de epotilona D en el tratamiento de enfermedades asociadas a Tau incluyendo enfermedad de Alzheimer |
US9717803B2 (en) | 2011-12-23 | 2017-08-01 | Innate Pharma | Enzymatic conjugation of polypeptides |
EP2872894B1 (en) | 2012-07-13 | 2019-04-17 | Innate Pharma | Screening of conjugated antibodies |
US10036010B2 (en) | 2012-11-09 | 2018-07-31 | Innate Pharma | Recognition tags for TGase-mediated conjugation |
WO2014140300A1 (en) | 2013-03-15 | 2014-09-18 | Innate Pharma | Solid phase tgase-mediated conjugation of antibodies |
US10071169B2 (en) | 2013-06-20 | 2018-09-11 | Innate Pharma | Enzymatic conjugation of polypeptides |
AU2014283185B2 (en) | 2013-06-21 | 2019-05-02 | Innate Pharma | Enzymatic conjugation of polypeptides |
WO2019092148A1 (en) | 2017-11-10 | 2019-05-16 | Innate Pharma | Antibodies with functionalized glutamine residues |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT833828E (pt) * | 1995-06-09 | 2003-02-28 | Novartis Ag | Derivados de rapamicina |
US6495579B1 (en) * | 1996-12-02 | 2002-12-17 | Angiotech Pharmaceuticals, Inc. | Method for treating multiple sclerosis |
US6515016B2 (en) * | 1996-12-02 | 2003-02-04 | Angiotech Pharmaceuticals, Inc. | Composition and methods of paclitaxel for treating psoriasis |
IL131447A0 (en) * | 1997-02-18 | 2001-01-28 | Canji Inc | Combined tumor supressor gene therapy and chemotherapy in the treatment of neoplasms |
GB9801231D0 (en) * | 1997-06-05 | 1998-03-18 | Merck & Co Inc | A method of treating cancer |
US6605599B1 (en) * | 1997-07-08 | 2003-08-12 | Bristol-Myers Squibb Company | Epothilone derivatives |
AU9340998A (en) * | 1997-08-09 | 1999-03-01 | Schering Aktiengesellschaft | New epothilone derivatives, method for producing same and their pharmaceutical use |
DE69818304T2 (de) * | 1997-12-04 | 2004-07-01 | Bristol-Myers Squibb Co. | Verfahren zur reduktion von oxiranyl-epothilonen zu olefinischen epothilonen |
US6302838B1 (en) * | 1998-02-25 | 2001-10-16 | Novartis Ag | Cancer treatment with epothilones |
FR2775187B1 (fr) * | 1998-02-25 | 2003-02-21 | Novartis Ag | Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo |
WO1999067253A2 (en) * | 1998-06-22 | 1999-12-29 | Novartis Ag | Desmethyl epothilones |
IL144519A0 (en) * | 1999-02-18 | 2002-05-23 | Schering Ag | 16-halogen-epothilone derivatives, method for producing them and their pharmaceutical use |
PE20010116A1 (es) * | 1999-04-30 | 2001-02-15 | Schering Ag | Derivados de 6-alquenil-, 6-alquinil- y 6-epoxi-epotilona, procedimientos para su preparacion |
EP2266607A3 (en) * | 1999-10-01 | 2011-04-20 | Immunogen, Inc. | Immunoconjugates for treating cancer |
DE10020517A1 (de) * | 2000-04-19 | 2001-10-25 | Schering Ag | Neue Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung |
US20020045609A1 (en) * | 2000-05-26 | 2002-04-18 | Gary Ashley | Epothilone derivatives and methods for making and using the same |
GB0013643D0 (en) * | 2000-05-31 | 2000-07-26 | Unilever Plc | Targeted moieties for use in bleach catalysts |
JP2004532888A (ja) * | 2001-06-01 | 2004-10-28 | ブリストル−マイヤーズ スクイブ カンパニー | エポチロン誘導体 |
-
2002
- 2002-03-01 EP EP02004745A patent/EP1340498A1/en not_active Withdrawn
-
2003
- 2003-02-28 YU YU76404A patent/YU76404A/sh unknown
- 2003-02-28 IL IL16375203A patent/IL163752A0/xx unknown
- 2003-02-28 CN CNB038097613A patent/CN100473381C/zh not_active Expired - Fee Related
- 2003-02-28 CA CA002477403A patent/CA2477403A1/en not_active Abandoned
- 2003-02-28 KR KR10-2004-7013549A patent/KR20040095244A/ko not_active Application Discontinuation
- 2003-02-28 WO PCT/EP2003/002085 patent/WO2003074053A1/en active Application Filing
- 2003-02-28 JP JP2003572570A patent/JP2005525360A/ja active Pending
- 2003-02-28 BR BR0308154-0A patent/BR0308154A/pt not_active Withdrawn
- 2003-02-28 NZ NZ546617A patent/NZ546617A/en unknown
- 2003-02-28 EP EP03743360A patent/EP1480643A1/en not_active Withdrawn
- 2003-02-28 RU RU2004129325/15A patent/RU2351330C2/ru active
- 2003-02-28 AU AU2003215618A patent/AU2003215618B2/en not_active Expired - Fee Related
- 2003-02-28 UA UA20040907817A patent/UA83798C2/ru unknown
- 2003-02-28 US US10/375,043 patent/US20040019088A1/en not_active Abandoned
- 2003-02-28 MX MXPA04008450A patent/MXPA04008450A/es not_active Application Discontinuation
- 2003-02-28 PL PL03370768A patent/PL370768A1/xx not_active Application Discontinuation
- 2003-03-03 AR ARP030100696A patent/AR038712A1/es unknown
-
2004
- 2004-09-01 CR CR7444A patent/CR7444A/es not_active Application Discontinuation
- 2004-09-28 HR HRP20040892 patent/HRP20040892A2/hr not_active Application Discontinuation
- 2004-09-30 NO NO20044175A patent/NO20044175L/no not_active Application Discontinuation
- 2004-09-30 ZA ZA200407905A patent/ZA200407905B/en unknown
- 2004-09-30 EC EC2004005340A patent/ECSP045340A/es unknown
-
2006
- 2006-01-04 HK HK06100157.3A patent/HK1079998A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
CN1649587A (zh) | 2005-08-03 |
AU2003215618B2 (en) | 2009-06-04 |
EP1340498A1 (en) | 2003-09-03 |
RU2004129325A (ru) | 2005-07-10 |
CR7444A (es) | 2005-10-05 |
IL163752A0 (en) | 2005-12-18 |
EP1480643A1 (en) | 2004-12-01 |
CN100473381C (zh) | 2009-04-01 |
ZA200407905B (en) | 2006-04-26 |
ECSP045340A (es) | 2004-11-26 |
AR038712A1 (es) | 2005-01-26 |
HK1079998A1 (zh) | 2006-04-21 |
KR20040095244A (ko) | 2004-11-12 |
YU76404A (sh) | 2006-08-17 |
BR0308154A (pt) | 2005-01-04 |
PL370768A1 (en) | 2005-05-30 |
RU2351330C2 (ru) | 2009-04-10 |
WO2003074053A1 (en) | 2003-09-12 |
UA83798C2 (ru) | 2008-08-26 |
CA2477403A1 (en) | 2003-09-12 |
HRP20040892A2 (en) | 2004-12-31 |
AU2003215618A1 (en) | 2003-09-16 |
JP2005525360A (ja) | 2005-08-25 |
US20040019088A1 (en) | 2004-01-29 |
NZ546617A (en) | 2007-12-21 |
MXPA04008450A (es) | 2005-07-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20044175L (no) | Anvendelse av epotiloner ved behandling av hjernesykdom relatert til proliferative prosesser | |
CY2015025I1 (el) | Μεθοδοι για την αντιμετωπιση της νοσου παρκινσον | |
EP1643986A4 (en) | PHENYLCARBOXYLATE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | |
ATE550338T1 (de) | Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit | |
DE602006019838D1 (de) | Piperazinsubstituierte benzothiophene zur behandlung von geisteskrankheiten | |
NO20052894D0 (no) | 4-tetrazolyl-4-fenylpiperidin-derivater for behandling av smerte | |
DE602005007717D1 (de) | Imidazolverbindungen zur behandlung von neurodegenerativen erkrankungen | |
EP1641748A4 (en) | INHIBITORS OF BETA-SECRETASE BASED ON N-ALKYL PHENYLCARBOXAMIDE FOR THE TREATMENT OF ALZHEIMER'S DISEASE | |
HK1116202A1 (en) | Means and methods for the treatment of tumorous diseases | |
IS8142A (is) | Læknislyf gagnleg til meðferðar á verkjum | |
EP1855679A4 (en) | INHIBITORS OF AMINOMETHYL BETA-SECRETASE IN THE TREATMENT OF ALZHEIMER'S DISEASE | |
CY2018006I1 (el) | Θεραπευτικο σχημα κλαδριβινης για την θεραπευτικη αντιμετωπιση της σκληρυνσης κατα πλακας | |
GB0329874D0 (en) | Compounds useful for the treatment of diseases | |
PL1685125T3 (pl) | Pochodne pirrolowe użyteczne do leczenia chorób proliferacyjnych | |
ATE443704T1 (de) | Pyridopyrimidinone zur behandlung von krebserkrankungen | |
NO20045554L (no) | Fremgangsmate for behandling av diabetes | |
ATE439843T1 (de) | S-mirtazapin zur behandlung von hitzewallungen | |
GB0320238D0 (en) | Treatment of disease | |
IL184849A0 (en) | Organic compounds useful for the treatment of alzheimer's disease, their use and method of preparation | |
ATE482707T1 (de) | 1-ä2h-1-benzopyran-2-on-8-ylü- piperazin- derivate zur behandlung von schmerzen | |
EP1613318A4 (en) | COMPOUNDS AND ITS USE FOR THE TREATMENT OF DIABETES AND RELATED DISEASES | |
DE602005017605D1 (de) | Pyrrolopyrimidinderivate zur behandlung proliferativer krankheiten | |
FR2855050B1 (fr) | Procede de traitement cosmetique des rougeurs | |
PL1904060T3 (pl) | Zastosowanie pochodnych ftalocyjaniny do nie-fotodynamicznego leczenia chorób | |
ATE359270T1 (de) | Phenyl-piperidin-4-yliden-methyl-benzamidderiva e zur behandlung von schmerz oder magen-darm- erkrankungen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |